[go: up one dir, main page]

ECSP10010464A - Uso de ranolazina para el tratamiento de enfermedades cardiovasculares - Google Patents

Uso de ranolazina para el tratamiento de enfermedades cardiovasculares

Info

Publication number
ECSP10010464A
ECSP10010464A EC2010010464A ECSP10010464A ECSP10010464A EC SP10010464 A ECSP10010464 A EC SP10010464A EC 2010010464 A EC2010010464 A EC 2010010464A EC SP10010464 A ECSP10010464 A EC SP10010464A EC SP10010464 A ECSP10010464 A EC SP10010464A
Authority
EC
Ecuador
Prior art keywords
ranolazine
treatment
cardiovascular diseases
coronary intervention
administering
Prior art date
Application number
EC2010010464A
Other languages
English (en)
Inventor
Marcus Jerling
Andrew Wolff
Luiz Belardinelli
Whedy Wang
Ewa Prokopczuk
Louis Lange
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of ECSP10010464A publication Critical patent/ECSP10010464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se revela un método para reducir arritmias asociadas con intervención coronaria en un paciente, que comprende administrar una composición farmacéutica que comprende ranolazina antes de la intervención coronaria.
EC2010010464A 2008-02-13 2010-09-06 Uso de ranolazina para el tratamiento de enfermedades cardiovasculares ECSP10010464A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/030,468 US20090111826A1 (en) 2007-02-13 2008-02-13 Use of ranolazine for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
ECSP10010464A true ECSP10010464A (es) 2010-10-30

Family

ID=40626660

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010464A ECSP10010464A (es) 2008-02-13 2010-09-06 Uso de ranolazina para el tratamiento de enfermedades cardiovasculares

Country Status (13)

Country Link
US (2) US20090111826A1 (es)
EP (1) EP2252295A1 (es)
JP (1) JP2011511844A (es)
KR (1) KR20110013352A (es)
AU (1) AU2009214639A1 (es)
BR (1) BRPI0907956A2 (es)
CA (1) CA2714301A1 (es)
CO (1) CO6531499A2 (es)
EA (1) EA201070918A1 (es)
EC (1) ECSP10010464A (es)
IL (1) IL207247A0 (es)
MX (1) MX2010008433A (es)
WO (1) WO2009102886A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165304A0 (en) * 2002-05-21 2006-01-15 Cv Therapeutics Inc Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
US20100056536A1 (en) * 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
MX2014000095A (es) * 2011-07-07 2014-05-28 Janssen Diagnostics Llc Método de análisis de trastornos cardiovasculares y usos del mismo.
CN116115669B (zh) * 2021-09-27 2025-05-06 天士力医药集团股份有限公司 一种治疗心肌缺血的药物组合物及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
US20030220312A1 (en) * 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
GB0028414D0 (en) * 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
AU2003210975A1 (en) * 2002-02-08 2003-09-02 Mitokor Compounds for inhibiting insulin secretion and methods related thereto
NZ534682A (en) * 2002-02-15 2006-10-27 Cv Therapeutics Inc Polymer coating for medical devices
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
IL165304A0 (en) * 2002-05-21 2006-01-15 Cv Therapeutics Inc Method of treating diabetes
CA2517981A1 (en) * 2003-03-05 2004-09-16 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050074425A1 (en) * 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD OF TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF ACUTE INCREASES IN HYPERGLYCEMIA AND / OR ACUTE INCREASES OF FREE FATTY ACID FLOWS
RU2007121707A (ru) * 2004-11-09 2008-12-20 Си Ви ТЕРАПЬЮТИКС Применение ранолазина в комбинации с по меньшей мере одним агентом совместного ремоделирования при лечении сердечной недостаточности
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
WO2006099244A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
EP2136780A1 (en) * 2007-02-13 2009-12-30 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2687381A1 (en) * 2007-05-31 2008-12-04 Cv Therapeutics, Inc. Method of treating diabetes
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪

Also Published As

Publication number Publication date
EP2252295A1 (en) 2010-11-24
AU2009214639A1 (en) 2009-08-20
IL207247A0 (en) 2010-12-30
EA201070918A1 (ru) 2011-02-28
KR20110013352A (ko) 2011-02-09
WO2009102886A1 (en) 2009-08-20
BRPI0907956A2 (pt) 2015-08-04
JP2011511844A (ja) 2011-04-14
CA2714301A1 (en) 2009-08-20
US20100035890A1 (en) 2010-02-11
MX2010008433A (es) 2011-03-02
US20090111826A1 (en) 2009-04-30
CO6531499A2 (es) 2012-09-28

Similar Documents

Publication Publication Date Title
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
UY32414A (es) Nuevos metodos
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso
CR11869A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
CO6541630A2 (es) Combinación teobromina con un descongestivo y su uso para el tratamiento de la tos
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
AR082594A1 (es) Docosahexanoato de pantenilo y su uso para el tratamiento y prevencion de enfermedades cardiovasculares
AR067351A1 (es) Combinacion de picotamida con nafronil